本文選題：鈦 + 殼聚糖-阿托伐他汀偶聯(lián)物��； 參考：《重慶大學(xué)》2013年碩士論文

【摘要】：鈦材作為一種生物醫(yī)用植入材料，被廣泛地應(yīng)用于臨床治療，如假肢、心血管植入物和種植牙等植入體。然而，在某些情形下，鈦材植入體內(nèi)幾小時(shí)后會(huì)發(fā)生炎癥反應(yīng)，臨床表現(xiàn)主要包括植入部位發(fā)紅、發(fā)熱和疼痛等癥狀。 本文旨在以鈦材為基材，通過改善其表面的相關(guān)特性，進(jìn)而減少組織對鈦材的炎癥響應(yīng)，提高鈦材的生物相容性。首先對合成的殼聚糖-阿托伐他汀偶聯(lián)物通過FTIR、H1NMR進(jìn)行了表征，然后在鈦材表面形成聚多巴胺薄膜作為中間層來固定殼聚糖-阿托伐他汀偶聯(lián)物，分別用場發(fā)射掃描電鏡（FE-SEM），X-射線光譜圖（XPS）和接觸角進(jìn)行表征。實(shí)驗(yàn)結(jié)果表明，殼聚糖-阿托伐他汀偶聯(lián)物成功固定在鈦材表面。相關(guān)細(xì)胞實(shí)驗(yàn)表明，接種在固載殼聚糖-阿托伐他汀偶聯(lián)物的鈦材上的內(nèi)皮細(xì)胞分別經(jīng)過4天和7天的培養(yǎng)后較其他對照組表現(xiàn)出更高的細(xì)胞活性和更低的乳酸脫氫酶產(chǎn)物（p0.01）。同時(shí)，在固載殼聚糖-阿托伐他汀偶聯(lián)物的鈦材上，，RAW264.7細(xì)胞較純鈦基材表現(xiàn)出更低水平的一氧化氮（NO）、酸性磷酸酶（ACP）活性、活性氧（ROS）和前炎癥因子包括腫瘤壞死因子（TNF-α）和白介素（IL-1β）（p0.01）。該結(jié)果表明，固載殼聚糖-阿托伐他汀偶聯(lián)物的鈦材能抑制巨噬細(xì)胞的炎癥響應(yīng)且具有更好的生物相容性。本研究為構(gòu)建生物功能性鈦基材植入物進(jìn)一步用于生物醫(yī)藥領(lǐng)域提供了新的參考方法。
[Abstract]:Titanium, as a biomedical implant, is widely used in clinical treatment, such as prostheses, cardiovascular implants and dental implants. However, in some cases, a few hours after titanium implantation, inflammation occurs, including symptoms such as redness, fever and pain at the implant site. Furthermore, the inflammatory response of tissue to titanium is reduced, and the biocompatibility of titanium is improved. The synthesized chitosan-Atto valvastatin conjugate was characterized by FTIR H 1 NMR, and then the poly dopamine film was formed on the titanium surface as the intermediate layer to immobilize the chitosan-Atto vastatin conjugate. Field emission scanning electron microscopy (SEM) and contact angle were used to characterize the results. The results showed that chitosan-Atto vastatin conjugate was successfully immobilized on titanium surface. The related cell experiments showed that the endothelial cells inoculated with chitosan-Atto vastatin conjugate showed higher cell activity and lower lactate dehydrogenase product than those of other control groups after 4 and 7 days culture respectively. At the same time, RAW264.7 cells exhibited lower activity of nitric oxide (no), acid phosphatase (ACP) and proinflammatory factors (including tumor necrosis factor TNF- 偽) and interleukin-1 尾 (p0.01) than pure titanium substrates. The results showed that titanium supported on chitosan-Atto vastatin conjugate could inhibit the inflammatory response of macrophages and have better biocompatibility. This study provides a new reference method for the construction of biofunctional titanium substrate implants for biomedical applications.
【學(xué)位授予單位】：重慶大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2013
【分類號】：R318.08

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 楊繼章,楊樹民;他汀類藥物的非降脂作用及臨床應(yīng)用[J];上海醫(yī)藥;2003年10期

本文編號：2000144